GEN Stock Overview
Provides DNA analysis and congenital diseases diagnostic services in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genomed Spólka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł28.00 |
| 52 Week High | zł33.40 |
| 52 Week Low | zł25.00 |
| Beta | -0.026 |
| 1 Month Change | 5.26% |
| 3 Month Change | 0.72% |
| 1 Year Change | -8.50% |
| 3 Year Change | -18.13% |
| 5 Year Change | 1.45% |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| GEN | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.0% |
| 1Y | -8.5% | -19.9% | 4.4% |
Return vs Industry: GEN exceeded the Polish Biotechs industry which returned -19.9% over the past year.
Return vs Market: GEN underperformed the Polish Market which returned 4.4% over the past year.
Price Volatility
| GEN volatility | |
|---|---|
| GEN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine GEN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 48 | Anna Boguszewska-Chachulska | www.genomed.pl |
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology.
Genomed Spólka Akcyjna Fundamentals Summary
| GEN fundamental statistics | |
|---|---|
| Market cap | zł37.00m |
| Earnings (TTM) | zł877.20k |
| Revenue (TTM) | zł23.06m |
42.2x
P/E Ratio1.6x
P/S RatioIs GEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEN income statement (TTM) | |
|---|---|
| Revenue | zł23.06m |
| Cost of Revenue | zł8.54m |
| Gross Profit | zł14.53m |
| Other Expenses | zł13.65m |
| Earnings | zł877.20k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 62.98% |
| Net Profit Margin | 3.80% |
| Debt/Equity Ratio | 0% |
How did GEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 01:56 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genomed Spólka Akcyjna is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|